USPTO Patent Applications - Pharma (A61K)

NACA Tablets Inhibit Vision Reduction in Usher Syndrome Patients

The USPTO has published a patent application (US20260083688A1) detailing compositions and methods for treating Usher syndrome associated retinitis pigmentosa using N-acetylcysteine amide (NACA) tablets. The application outlines specific dosages and claims to inhibit vision degradation and protect retinal sensitivity in patients.

Patent Application: Reversing Dexmedetomidine Sedation

The USPTO has published a patent application (US20260083689A1) detailing methods and compositions for reversing dexmedetomidine sedation using dextroamphetamine and/or lisdexamfetamine. The application was filed on October 7, 2025, by inventors Ken Solt, Oluwaseun Johnson-Akeju, and Emery N. Brown.

Patent Application for Treating Disease with Dichlorphenamide

The USPTO has published a patent application (US20260083692A1) from Strongbridge Dublin Limited for methods of treating disease using dichlorphenamide in conjunction with an organic anion transporter-1 (OAT1) substrate. The application details methods for administering the compounds and monitoring patient response and toxicity.

Intranasal Pharmaceutical Composition for Migraine Treatment

The USPTO has published a patent application (US20260083693A1) for an intranasal pharmaceutical composition containing ibuprofen and ketoprofen for treating migraine and headaches. The application details a method for manufacturing preparations with a combination of these active ingredients at reduced dosages compared to oral administration.

Patent Application: Composition for Controlling Aquatic Organism Infections

The USPTO has published a new patent application (US20260083697A1) from B. G. Negev Technologies and Applications Ltd. The application details a composition containing an esterified fatty acid for preventing or treating monogenean infections in aquatic organisms.

Patent Application: Synergistic Stimulation for Cystic Fibrosis Mucus Obstruction

The USPTO has published a new patent application (US20260083698A1) detailing methods for treating mucus obstruction in cystic fibrosis and other disorders. The application, filed on September 19, 2023, describes a combination therapy involving a b-adrenergic agonist or adenylate cyclase activator with a cholinergic agonist.

Patent Application for Psychoactive Medicines Treating Disorders

The USPTO has published patent application US20260083699A1 by Transcend Therapeutics, Inc. The application details psychoactive medicines, including 2C-B and cathinones, for treating psychiatric and neurological conditions. The filing date was December 4, 2025.

Patent Application: Methods Treat/Prevent Protein Aggregation Diseases Using Sulfatase Inhibitor

The USPTO has published a new patent application (US20260083700A1) detailing methods for treating and/or preventing protein-aggregation diseases by administering a sulfatase inhibitor. The application was filed on September 26, 2025, by inventors Manuel J. Muñoz, Ángel M. Carrión, and Mercedes M. Pérez-Jiménez.

Patent Application for Inflammatory Condition Treatment Compositions

The USPTO has published a new patent application (US20260083701A1) for compositions and methods related to the treatment of inflammatory conditions. The application details compounds and formulations aimed at managing inflammation and associated symptoms like dryness, itching, and redness.

Patent Application: Inhalation Formulation for Treating IPF Disease

The USPTO has published a patent application (US20260083702A1) detailing an inhalation formulation for treating Idiopathic Pulmonary Fibrosis (IPF) disease. The application describes formulations using specific drugs like apremilast and roflumilast, aiming to improve bioavailability and clinical efficacy compared to oral administration.

USPTO Patent Application for Indoline Derivatives as Serotonergic Agents

The USPTO has published a patent application (US20260083703A1) for indoline derivatives intended for use as serotonergic agents. The application details potential treatments for disorders related to serotonin receptor activation, including psychosis, mental illnesses, and CNS disorders.

Gamma-hydroxybutyrate Formulations with Improved Pharmacokinetics

The USPTO has published a new patent application, US20260083696A1, detailing modified release formulations of gamma-hydroxybutyrate with improved dissolution and pharmacokinetic properties. The application was filed on October 1, 2025, by inventors Jordan Dubow, Claire Megret, Hervé Guillard, and Jean-François Dubuisson.

Patent Application: Composition for Mitigating Veisalgia and Nausea

The USPTO has published a patent application (US20260083695A1) for a composition designed to reduce veisalgia (hangover) symptoms and nausea. The application details an orally deliverable formulation containing dihydromyricetin, acetylcysteine, and specific antiemetics, with a filing date of September 10, 2025.

Composition of L-leucine and fish oil for muscle health

The USPTO has published a patent application (US20260083694A1) for a composition comprising L-leucine and fish oil, intended for muscle health and the prevention of muscle mass and strength loss. The application was filed by ABIOGEN PHARMA S.P.A.

Patent Application for Dispersible Pharmaceutical Formulations

The USPTO has published patent application US20260083690A1 concerning dispersible pharmaceutical formulations of a specific chemical compound. The application details the composition and potential uses of these formulations.

Skin Barrier Film System Patent Application

The USPTO has published a new patent application, US20260083684A1, for a skin barrier film system. The application details a system comprising a film layer, adhesive, impregnated treatment, and a removable layer, designed to accommodate patient physical attributes. The filing date was September 24, 2025.

Sunscreen Compositions and Methods of Use

The USPTO has published a patent application from Mary Kay Inc. detailing new sunscreen compositions designed to protect skin from UV radiation. The application describes specific formulations involving film formers and organic UV filters, along with methods of making and using these compositions.

KAO CORPORATION patent for hair treatment agent

The USPTO has published a patent application by KAO CORPORATION for a hair treatment agent. The application, filed on May 31, 2023, details a specific formulation involving film-forming polymers and organopolysiloxanes.

Cannabis Products and Methods Patent Application

The USPTO has published a patent application (US20260083661A1) for cannabis-based products and methods, including lotions, soaps, perfumes, and teas. The application was filed on October 7, 2025, and lists Lawrence Lanier Long as the inventor.

Oxazolidinone Liposome Compositions with Improved Storage Stability

The USPTO has published a new patent application from Akagera Medicines, Inc. detailing oxazolidinone liposome compositions designed for improved storage stability. The application, filed on December 2, 2025, describes methods for manufacturing and using these compositions.

High-Bioactivity Goat Colostrum Powder Preparation Method

The USPTO has published a patent application detailing a method for preparing a high-bioactivity goat colostrum composite freeze-dried powder. The invention focuses on enhancing the stability and survival rate of probiotics within the powder through encapsulation techniques.

Patent for Spray-Dried Amorphous Solid Dispersions Using Polyvinyl Alcohol

The USPTO has published a new patent application (US20260083676A1) detailing a method for preparing spray-dried amorphous solid dispersions of active pharmaceutical ingredients using polyvinyl alcohol. The application was filed on September 14, 2023, by inventors Lena Mueller, Laura Halstenberg, Thomas Kipping, and Nicole Di Gallo.

Patent Application: Solid Medicinal Forms with Stabilised Active Ingredient

The USPTO has published a new patent application (US20260083677A1) from Astellas Pharma Inc. The application describes solid medicinal forms containing active ingredients stabilized with specific drying agents, aiming for reduced moisture content. This is a new patent filing, not a regulatory rule or guidance.

Oral GLP-1 Compound Dosing Patent Application

The USPTO has published a patent application (US20260083678A1) related to oral dosing of GLP-1 compounds. The application was filed on December 3, 2025, by inventors Flemming S. Nielsen and Per Sauerberg, and relates to improved uses of GLP-1 peptides in oral therapy.

Adagrasib Solid Pharmaceutical Compositions for Treating Cancer

The USPTO has published a new patent application (US20260083679A1) detailing solid pharmaceutical compositions containing adagrasib for treating cancer. The application, filed on December 3, 2025, includes methods for manufacturing these compositions and treating cancer.

Mesoporous Nano-Magnesium Oxide for Drug Loading

The USPTO has published a patent application for a mesoporous nano-magnesium oxide material designed for drug loading. The application details the material's properties, including particle size and pore structure, and outlines a preparation method involving magnesium oxalate and CTAB.

Patent Application: Spray Dried Lipid Nanoparticle Formulations

The USPTO has published a patent application (US20260083681A1) detailing formulations for spray-dried lipid nanoparticle matrix particles. The application, filed on September 16, 2025, describes a composition including lipid nanoparticles, a buffer system, and a barrier matrix stabilizer. This publication is part of the patent application process and does not represent a final grant or regulatory requirement.

Kit for Drug-Containing Nanoparticles and Composition for Drug Delivery

The USPTO has published a new patent application (US20260083682A1) by SAMYANG HOLDINGS CORPORATION for a kit and composition for constructing drug-containing nanoparticles for enhanced drug delivery. The application details a method utilizing cationic compounds and anionic polymers to improve cellular drug delivery efficiency.

Protein Nanospheres for Treating Chemotherapy Dysfunction

The USPTO has published a patent application (US20260083683A1) for protein nanospheres designed to treat dysfunction caused by chemotherapy and immunosuppressive therapy. The application details the manufacture and use of fibrinogen-coated albumin spheres (FAS) and High-Fibrinogen Spheres (HFS) for mitigating toxic effects of cancer treatments.

Patent Application for Genome Editing Compositions and Methods

The USPTO has published a new patent application (US20260083860A1) for genome editing compositions and methods. The application, filed on August 19, 2025, by inventors Oscar ALVAREZ, Ming-Yue LEE, and Blair B. MADISON, details methods and compositions for functional genetic modifications.

CRISPR Methods Targeting CD70 Expression for Engineered Cells

The USPTO has published a patent application (US20260083861A1) filed by Editas Medicine, Inc. The application describes CRISPR-related systems and methods for targeting the CD70 gene expression in engineered cells, particularly T cells, for potential therapeutic applications.

Patent Application: Treating Brain Diseases with rAAV Particles

The USPTO has published a new patent application (US20260083862A1) from the University of Iowa Research Foundation detailing methods for treating brain diseases using rAAV particles administered via the cisterna magna. The application was filed on May 19, 2025.

Patent Application for Contrast Agents in Diagnostic Imaging

The USPTO has published a patent application (US20260083864A1) for a new class of compounds intended for use as contrast agents in diagnostic imaging, including computed tomography (CT) and magnetic resonance imaging (MRI). The application details specific compound formulas, metal chelates, and preparation methods.

USPTO Patent Application for PSMA Ligands

The USPTO has published a new patent application (US20260083865A1) filed by 3B Pharmaceuticals GMBH for prostate specific membrane antigen (PSMA) ligands. The application details a compound of Formula (I) and its use in treating cancer.

Patent Application: Tumor Targeting Methods and Reagents

The USPTO has published a patent application (US20260083867A1) detailing methods and reagents for tumor targeting in cancer treatment. The application, filed on November 21, 2025, describes a combination therapeutic approach using agents with different biodistributions to enhance efficacy and reduce toxicity.

Patent Application: Compositions with Sophorolipids and Lactic Acid

The USPTO has published a new patent application (US20260083655A1) filed by Evonik Operations GmbH. The application describes compositions containing sophorolipids and lactic acid for cleaning or skin moisturizing. This is a routine filing for a new patent application.

Patent Application for Hyaluronic Acid Production Stimulation

The USPTO has published a new patent application (US20260083656A1) filed by Alastin Skincare, Inc. The application details compositions and methods for stimulating intrinsic hyaluronic acid production to improve skin moisture and elasticity. This is a routine publication of a patent application.

Patent Application for Whitening Cosmetic Composition with Artemisinic Acid

The USPTO has published a patent application (US20260083657A1) for a whitening cosmetic composition containing artemisinic acid, nicotinamide, and/or glutathione. The application, filed by Yunnan Botanee Bio-Technology Group Co., Ltd., describes a formulation designed to inhibit melanin production and reduce skin irritation.

Cleansing composition with carnosine, magnesium, caffeine

The USPTO has published a new patent application (US20260083658A1) for a personal cleansing composition. The composition includes carnosine, magnesium salt, caffeine, and transdermal absorption enhancers, designed for use in products like shower gels and soaps.

Skincare Therapeutic Balm Preparation Method Patent Application

The USPTO has published a patent application (US20260083662A1) for a skincare and therapeutic balm preparation method. The application, filed by Fine Washed LLC, details a method combining Ethiopian black seed oil with Illinois sourced beef tallow.

Botanical Compositions and Methods of Production and Use

The USPTO has published a new patent application, US20260083663A1, detailing botanical compositions with plant extracts and their preparation methods. The application was filed on September 11, 2023, and is scheduled for publication on March 26, 2026. This represents a new disclosure of potential intellectual property in the pharmaceutical sector.

Patent Application: Intrathecal T regulatory cells for Multiple Sclerosis Treatment

The USPTO has published a patent application (US20260083664A1) for a medicinal product involving intrathecal administration of T regulatory cells for treating multiple sclerosis. The application was filed on December 3, 2025, by inventors Piotr Trzonkowski and Kamil Chwojnicki.

USPTO Patent for Implantable Biodegradable Drug Delivery Devices

The USPTO has published a patent application (US20260083665A1) for implantable and biodegradable drug delivery devices. The invention aims to deliver active pharmaceutical ingredients directly to target tissue sites using layered biodegradable polymers.

USPTO Patent Application for Disease Treatment Method

The USPTO has published patent application US20260083666A1 for a method of treating diseases and ameliorating pain by administering a composition to the ear canal. The application was filed on April 10, 2025, and published on March 26, 2026.

Sulforaphane Supplement in Gummy Form Patent Application

The USPTO has published a patent application (US20260083667A1) for a sulforaphane supplement in gummy form. The application, filed by Sensory Scout LLC, describes a composition including sulforaphane, glucoraphanin, and myrosinase immobilized within a gummy matrix. This represents a new patent filing for a novel supplement formulation.

USPTO Patent for Orally Administered Corticosteroid Compositions

The USPTO has published a new patent application, US20260083668A1, for orally administered corticosteroid compositions. The patent, filed on November 28, 2025, by inventors Stephen Perrett, Fredric Jay Cohen, and Gopi M. Venkatesh, details pharmaceutical compositions and methods for treating gastrointestinal inflammation.

Aqueous Gel Composition for Administering Active Agents

The USPTO has published a new patent application, US20260083669A1, filed by Acousia Therapeutics GmbH. The application describes an aqueous gel composition useful for administering pharmaceutically active agents, particularly for transtympanic administration.

Adenovirus Formulation with Citrate Buffer and Salt

The USPTO has published a new patent application (US20260083670A1) for an adenovirus formulation. The formulation includes a recombinant adenovirus, citrate buffer, cyclodextrin compound, and salt, with a pH between 5.5 and 6.5, and is free of non-ionic detergent. The invention also covers a method for preserving adenoviruses using this formulation.

Patent Application for Stabilized Galectin-9 Protein Pharmaceutical Formulation

The USPTO has published a patent application (US20260083671A1) for a stabilized pharmaceutical formulation containing a recombinant stabilized galectin-9 protein. The application details a formulation designed for improved stability through the combination of a buffer and a stabilizer.

Oil-in-water emulsions for topical administration with hyaluronan

The USPTO has published a patent application (US20260083673A1) for oil-in-water emulsions containing hyaluronan for topical administration. The application details formulations for treating various dermatological conditions, including inflammatory dermatoses, acne, alopecia, and fibrosing pathologies.